JOURNAL FOR IMMUNOTHERAPY OF CANCER

JOURNAL FOR IMMUNOTHERAPY OF CANCER Journal

publication venue for

Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. 11. 2023
FIRST-IN-HUMAN PHASE 1A STUDY OF NG-641, A TUMOUR-SELECTIVE VECTOR EXPRESSING A FAP-TAC BISPECIFIC ANTIBODY AND IMMUNE ENHANCER MODULE, IN PATIENTS WITH METASTATIC/ADVANCED EPITHELIAL TUMOURS (STAR) 2022
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. 10. 2022
A PHASE 1B/2 UMBRELLA STUDY OF ANTI-PD-1 SASANLIMAB IN COMBINATION WITH OTHER THERAPIES FOR PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC): THE LANDSCAPE 1011 TRIAL IN PROGRESS 2021

Electronic International Standard Serial Number (EISSN)

2051-1426

journal abbreviation

J IMMUNOTHER CANCER